ATE466069T1 - Peptid-konjugierte antikrebs-prodrugs - Google Patents
Peptid-konjugierte antikrebs-prodrugsInfo
- Publication number
- ATE466069T1 ATE466069T1 AT01967657T AT01967657T ATE466069T1 AT E466069 T1 ATE466069 T1 AT E466069T1 AT 01967657 T AT01967657 T AT 01967657T AT 01967657 T AT01967657 T AT 01967657T AT E466069 T1 ATE466069 T1 AT E466069T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- conjugated anti
- cancer
- chemotherapeutic drug
- cancer prodrugs
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22973300P | 2000-09-05 | 2000-09-05 | |
| PCT/IL2001/000839 WO2002020715A2 (en) | 2000-09-05 | 2001-09-05 | Peptide conjugated anti-cancer prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466069T1 true ATE466069T1 (de) | 2010-05-15 |
Family
ID=22862481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01967657T ATE466069T1 (de) | 2000-09-05 | 2001-09-05 | Peptid-konjugierte antikrebs-prodrugs |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7135547B2 (https=) |
| EP (2) | EP2272947B1 (https=) |
| AT (1) | ATE466069T1 (https=) |
| AU (1) | AU2001288025A1 (https=) |
| DE (1) | DE60141992D1 (https=) |
| IL (1) | IL154696A (https=) |
| WO (1) | WO2002020715A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| NZ564694A (en) * | 2003-04-22 | 2009-11-27 | Sod Conseils Rech Applic | Peptide vectors |
| AU2004248138B2 (en) * | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| AT412785B (de) | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| US7345069B2 (en) * | 2004-04-02 | 2008-03-18 | Wisconsin Alumni Research Foundation | Oxidative activation and episulfonium ion-mediated DNA alkylation-based anticancer |
| CA2623236A1 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
| KR20090088946A (ko) * | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | 씨디70에 결합하는 인간 항체 및 이의 용도 |
| WO2008139457A2 (en) * | 2007-05-10 | 2008-11-20 | Clear Direction Ltd. | Methods and compositions for drug targeting |
| KR101032860B1 (ko) * | 2008-10-22 | 2011-05-06 | 한국식품연구원 | 췌장 조직 특이적 유전자 ｍｍｐ1 |
| CN101747411B (zh) * | 2008-11-28 | 2012-07-25 | 北京大学 | 氨基酰色氨酰色氨酸三肽苄酯及其制备方法和应用 |
| EP2488874A4 (en) * | 2009-10-13 | 2013-08-14 | Univ Johns Hopkins | BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| HRP20150664T1 (hr) * | 2010-12-03 | 2015-07-31 | Adamed Sp. Z O.O. | Antikancerogeni fuzijski protein |
| PL394618A1 (pl) * | 2011-04-19 | 2012-10-22 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| US9081001B2 (en) | 2012-05-15 | 2015-07-14 | Wellstat Diagnostics, Llc | Diagnostic systems and instruments |
| US9213043B2 (en) | 2012-05-15 | 2015-12-15 | Wellstat Diagnostics, Llc | Clinical diagnostic system including instrument and cartridge |
| US9625465B2 (en) | 2012-05-15 | 2017-04-18 | Defined Diagnostics, Llc | Clinical diagnostic systems |
| US8946163B2 (en) * | 2012-11-19 | 2015-02-03 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
| US9155799B2 (en) | 2012-11-19 | 2015-10-13 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
| US8940684B2 (en) | 2012-11-19 | 2015-01-27 | Mimedx Group, Inc. | Cross-linked collagen comprising an antifungal agent |
| US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
| US10335433B2 (en) | 2013-04-10 | 2019-07-02 | Mimedx Group, Inc. | NDGA polymers and metal complexes thereof |
| US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
| US10449220B2 (en) | 2013-08-30 | 2019-10-22 | Mimedx Group, Inc. | Micronized placental compositions comprising a chelator |
| KR102272213B1 (ko) * | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US11104698B2 (en) | 2015-12-03 | 2021-08-31 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US11939609B2 (en) | 2017-07-24 | 2024-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system |
| CA3086751A1 (en) * | 2018-01-08 | 2019-07-11 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| KR102544277B1 (ko) * | 2020-01-15 | 2023-06-16 | 재단법인대구경북과학기술원 | 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도 |
| US20210402001A1 (en) * | 2020-06-30 | 2021-12-30 | David I. Cohen | Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers |
| TW202328170A (zh) * | 2021-09-14 | 2023-07-16 | 美商艾希利歐發展股份有限公司 | 可裂解連接子 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983000150A1 (en) * | 1981-07-02 | 1983-01-20 | Walton, Alan, G. | Glycosaminoglycan drug complexes |
| GB8907617D0 (en) * | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| CA2157388C (en) * | 1993-03-01 | 1998-12-15 | Daniel P. Witt | Analogs for specific oligosaccharide-protein interactions and uses thereof |
| AU684498B2 (en) | 1993-03-25 | 1997-12-18 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| US5612474A (en) * | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
| US5871723A (en) | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
| DE19701141C1 (de) * | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
-
2001
- 2001-09-05 AT AT01967657T patent/ATE466069T1/de not_active IP Right Cessation
- 2001-09-05 DE DE60141992T patent/DE60141992D1/de not_active Expired - Lifetime
- 2001-09-05 IL IL154696A patent/IL154696A/en active IP Right Grant
- 2001-09-05 AU AU2001288025A patent/AU2001288025A1/en not_active Abandoned
- 2001-09-05 WO PCT/IL2001/000839 patent/WO2002020715A2/en not_active Ceased
- 2001-09-05 EP EP10156533.1A patent/EP2272947B1/en not_active Expired - Lifetime
- 2001-09-05 EP EP01967657A patent/EP1581615B1/en not_active Expired - Lifetime
-
2003
- 2003-03-05 US US10/382,240 patent/US7135547B2/en not_active Expired - Lifetime
-
2006
- 2006-11-02 US US11/555,939 patent/US7638127B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1581615B1 (en) | 2010-04-28 |
| US20030216298A1 (en) | 2003-11-20 |
| IL154696A0 (en) | 2003-09-17 |
| EP1581615A2 (en) | 2005-10-05 |
| AU2001288025A1 (en) | 2002-03-22 |
| DE60141992D1 (https=) | 2010-06-10 |
| US7135547B2 (en) | 2006-11-14 |
| US20070160573A1 (en) | 2007-07-12 |
| EP1581615A4 (en) | 2005-10-05 |
| WO2002020715A2 (en) | 2002-03-14 |
| EP2272947A1 (en) | 2011-01-12 |
| EP2272947B1 (en) | 2016-08-10 |
| AU2001288025A8 (en) | 2006-11-02 |
| WO2002020715A3 (en) | 2006-01-12 |
| US7638127B2 (en) | 2009-12-29 |
| IL154696A (en) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE466069T1 (de) | Peptid-konjugierte antikrebs-prodrugs | |
| HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
| WO2002000263A3 (en) | Tripeptide prodrug compounds | |
| DE60006100D1 (de) | Lang wirkende insulinotrope peptide | |
| TR200202183T2 (tr) | Peptidazla bölünebilen, hedeflenmiş antineoplastik ilaçlar ve terapetik kullanımları | |
| WO2001062300A3 (en) | Caspase activated prodrugs therapy | |
| HN2001000243A (es) | Inhibidores de metaloproteinasa del tipo pirimidin - 2, 4, 6 - triona | |
| ATE471161T1 (de) | Konjugierte prodrogen von cc-1065 analoga | |
| PT1178958E (pt) | N-cianometilamidas como inibidores de proteases | |
| DE60122335D1 (de) | Zusammensetzung auf der basis polymerer mizellen | |
| EA200200017A1 (ru) | Терапевтическое средство с ботулиническим нейротоксином | |
| WO2002013873A3 (en) | P97-active agent conjugates and their methods of use | |
| AU7001001A (en) | Modified forms of pharmacologically active agents and uses therefor | |
| TR200101120T2 (tr) | Serin proteaz inhibitörü | |
| GR3035593T3 (en) | Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases | |
| Nichifor et al. | Polymeric prodrugs of 5-fluorouracil | |
| AU2001264515A1 (en) | Melphalan derivatives and their use as cancer chemotherapeutic drugs | |
| ATE317846T1 (de) | Phosphoramidat-prodrugs | |
| WO2001085777A3 (en) | Therapeutic pore-forming peptides | |
| WO2001095945A3 (en) | Prodrug compounds cleavable by thimet oligopeptidase | |
| ATE349221T1 (de) | Extrakt mit antitumoraler und antitoxischer wirkung | |
| AU3739500A (en) | Protease resistant flint analogs | |
| SE0001916D0 (sv) | Novel formulation | |
| WO2002057246A3 (en) | Inhibitors of cruzipain and other cysteine proteases | |
| ATE301469T1 (de) | Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |